MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2016 International Congress

    Exosomes-injection to reproduce a mouse model of Parkinson’s disease: A preliminary report

    C. Han, J. Huang, K. Ma, Y. Shen, L. Liu, G. Zhang, X. Xu, J. Li, H. Jiang, S. Guo, Y. Xia, L. Wang, N. Xiong, T. Wang (Wuhan, People's Republic of China)

    Objective: To explore the pathogenicity of exosomes derived from Parkinson's disease (PD) patients' serum and healthy control's serum in vivo and verify the prion-like propagation…
  • 2016 International Congress

    Striatal PDE10 expression in Parkinson’s disease (PD) and healthy controls using [18F]MNI-659 PET imaging

    D.S. Russell, D.L. Jennings, O. Barret, G.D. Tamagnan, D. Alagille, J.P. Seibyl, K.L. Marek (New Haven, CT, USA)

    Objective: To evaluate the feasibility of [18F]MNI-659 PET, a striatal PDE10A imaging tracer, as a imaging biomarker in PD. Background: PDE10 is highly and specifically…
  • 2016 International Congress

    Heterozygous PINK1 p.G411S mutation increases risk for Parkinson’s disease (PD)

    W. Springer, A. Puschmann, F.C. Fiesel, M. Ando, T.R. Caulfield, K. Ogaki, M.G. Heckman, R. Hudec, E.D. James, G. Opala, J. Siuda, M. Boczarska-Jedynak, A. Friedman, D. Koziorowski, J.O. Aasly, T. Lynch, G.D. Mellick, M. Mohan, P.A. Silburn, Y. Sanotsky, C. Vilariño-Güell, M.J. Farrer, T. Dawson, Z.K. Wszolek, O.A. Ross (Jacksonville, FL, USA)

    Objective: To investigate the possible disease-association and pathogenic mechanisms of heterozygous PINK1 mutations from a genetic, functional, and structural perspective. Background: It has been postulated…
  • 2016 International Congress

    Mitochondrial Hsp90 inhibitor G-TTP triggers PINK1/parkin-dependent mitochondrial quality control

    F.C. Fiesel, J.D. Elle, H.R. Anneliese, H. Roman, S. Wolfdieter (Jacksonville, FL, USA)

    Objective: To characterize the response of cells treated with Gamitrinib-triphenylphosphonium (G-TTP) a mitochondrial targeted inhibitor of the chaperone Hsp90. Background: Upon dissipation of the mitochondrial…
  • 2016 International Congress

    Falls in Parkinson’s disease: Beware the short, slow steps

    A. Lieberman, A. Deep, S. Shafer, T. Lockhart (Phoenix, AZ, USA)

    Objective: To determine if step length influence falls in Parkinson's disease (PD) patients. Background: Falls are major cause of disability in PD. The objective of…
  • 2016 International Congress

    Cortical impairment as marker of dementia risk in probable REM sleep behavior disorder in Parkinson’s disease

    A.D. Santana-Vargas, H. Duran-Meza, J.D. Ramirez-Diossa, G.H. Terrazas Gonzalez, M. Lopez-Ruiz, G. Millan-Rosas, U. Jimenez-Correa (Mexico City, Mexico)

    Objective: To assess utility of Parkinson's disease-cognitive rating scale (PD-CRS) to detect Mild cognitive impairment (MCI) and dementia risk in a Parkinson's disease (PD) subpopulation.…
  • 2016 International Congress

    Stabilometry characteristics as objective Parkinson’s disease progression biomarkers

    I.V. Miliukhina, T.V. Sergeev, E.V. Gracheva, A.V. Kudrevatykh, M.D. Didur (Saint-Petersburg, Russia)

    Objective: We aimed to find stabilometry characteristics, which may be used as disease progression and postural instability early development markers. Background: Balance and gait disorders…
  • 2016 International Congress

    Generation and characterization of midbrain organoids from iPSCs of familial Parkinson’s disease

    E. Frattini, G. Monzio Compagnoni, S. Salani, P. Rinchetti, M. Nizzardo, M. Baccarin, N. Bresolin, G.P. Comi, S.P. Corti, A. Di Fonzo (Milan, Italy)

    Objective: To generate and characterize human pluripotent stem cell (iPSCs) - derived midbrain cerebral organoids of patients with Parkinson's disease. Background: Parkinson's disease is a…
  • 2016 International Congress

    Cyclic glycine-proline increased in the cerebrospinal fluid of Parkinson’s patients after supplementation of blackcurrant anthocyanins: Potential biomarker for treatment

    J. Guan, Y. Alamri, D. Fan, M. MacAskill, T. Anderson (Auckland, New Zealand)

    Objective: We evaluated the changes of insulin-like growth factor-1 bioavailability in the Parkinson's disease patients after 28 day supplementation of blackcurrant anthocyanin. Background: Elevated insulin-like…
  • 2016 International Congress

    In idiopathic Parkinson’s disease: The effect of using L-dopa on peripheral nerves

    M.E. Temir, F. Genç, Y. Biçer Gömceli, A. Yaman, A. Aybar, E. Karaçay (Antalya, Turkey)

    Objective: Idiopathic Parkinson's disease (IPD) is a chronic neurodegenerative disorder. Most of the clinicians believe that it is limited with motor and cognitive disorders. However,…
  • « Previous Page
  • 1
  • …
  • 1817
  • 1818
  • 1819
  • 1820
  • 1821
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley